Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in patients with type 2 diabetes and peripheral artery disease with intermittent claudication
CTR20210420Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), arteriosclerosis obliterans, intermittent claudication (IC), sponsored by Novo Nordisk. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)arteriosclerosis obliteransintermittent claudication (IC)
Beyond the preview
Go deeper on CTR20210420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210420.